In conventional thermocatalytic reactions under a reducing atmosphere, stabilization of the active Cu component and inhibition of over-reduction into metallic Cu are extremely challenging. In this study, Au@CuO core-shell nano-catalysts with different CuO shell thicknesses were synthesized, and the effect of the Au nano-core on Cu stability under a reducing atmosphere and the catalytic performance of Cu in the ethynylation of formaldehyde were investigated. The Au nano-core facilitates CuO dispersion and leads to an increase of 0.
View Article and Find Full Text PDFBackground: This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine.
Method: In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18-59 years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval. The safety and immunogenicity of the vaccine were evaluated.
Background: We evaluated an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for immunogenicity and safety in adults aged 18-59 years.
Methods: In this randomized, double-blinded, controlled trial, healthy adults received a medium dose (MD) or a high dose (HD) of the vaccine at an interval of either 14 days or 28 days. Neutralizing antibody (NAb) and anti-S and anti-N antibodies were detected at different times, and adverse reactions were monitored for 28 days after full immunization.
In the communication, by virtue of the excellent conductivity and great surface area of mesoporous carbon (FDU-15), the enhanced conductivity of Au NPs, and the good electrochemical response of polyphenol oxidase (PPO) to rutin, a PPO/AuNPs/FDU-15-modified electrode was used as a candidate for the determination of rutin in dark teas with satisfactory results.
View Article and Find Full Text PDFBackground: The development of a Sabin strain-based inactivated poliovirus vaccine (Sabin-IPV) is imperative to protecting against vaccine-associated paralytic poliomyelitis in developing countries.
Methods: In this double-blinded, parallel-group, noninferiority trial, eligible infants aged 60-90 days were randomly assigned in a ratio of 1:1 to receive either 3 doses of Sabin-IPV or Salk strain-based IPV (Salk-IPV) at 30-day intervals and a booster at the age of 18 months. Immunogenicity and safety were assessed on the basis of a protocol.